- Our view
- Buy
- Price then
- INR 3,386.3/-
- Target
- INR 4,288
- Upside
- 26.6%
- Market cap then
- INR 13,227.6 Cr.
Privi Speciality Chemicals manufactures and exports aroma and fragrance chemicals for global fragrance houses and FMCG companies. The report’s valuation implies a Buy, with a target price of INR 4,288 and potential upside of 26.6% from the stated current market price. Growth drivers include capacity expansion, higher-value products and backward integration, while execution, input costs and working capital remain key risks.
About Privi Speciality Chemicals
Established in 1993, Privi manufactures and exports aroma and fragrance chemicals. Its product range includes pinene, specialty products, musk, phenol and citral, with an emphasis on high-value applications. The company operates manufacturing sites in Mahad, Maharashtra and Jhagadia, Gujarat, with a combined capacity of 48,000 MTPA. Its customers include leading fragrance houses and FMCG companies, and its products are used in personal care, household cleaning and fine fragrances.
Investment Rationale
- Established customer relationships: Privi supplies the top 10 fragrance companies and major FMCG customers. Around 70% of revenue is under annual contracts with back-to-back input sourcing, which the report says supports margin sustainability.
- FY26 growth and operating improvement: FY26 revenue increased 22% to INR 2,563.7 Cr. while sales volumes grew 6.5% Y-o-Y. The report links performance to demand, product mix, realisations and operating efficiencies.
- Structural margin drivers: FY26 EBITDA margin improved by 362 bps. The report cites CST backward integration, fixed-cost dilution through debottlenecking and higher-value products including Galaxmusk, Prionyl and Amber Woody Xtreme.
- Capacity expansion: Three phases are planned to expand capacity from 48,000 MTPA to 72,000 MTPA, with commissioning targeted by Sep’26, Sep’27 and Sep’28. Management has reaffirmed its “5K:1K” target of INR 5,000 Cr revenue and INR 1,000 Cr+ EBITDA by FY29–30.
- Promoter entity merger: The proposed merger of Privi Fine Sciences (PFSPL) has received SEBI approval and is targeted for Dec’26; the report says it will add to existing capacity.
Privi Speciality Chemicals Key Financials
| Particulars | FY24 | FY25 | FY26 | Q1-FY27 |
|---|---|---|---|---|
| Operating Revenue | 1,752 | 2,101 | 2,564 | 666 |
| Growth Y-o-Y % | 9.0% | 19.9% | 22.0% | 19.2% |
| EBITDA (excl. other income) | 325.0 | 453.5 | 646.2 | 152.3 |
| PAT | 95.4 | 184.8 | 316.7 | 82.8 |
| EBITDA % | 18.5% | 21.6% | 25.2% | 22.9%* |
| PAT % | 5.4% | 8.7% | 12.3% | 12.2% |
| Total Debt | 1,008.2 | 1,142.8 | 1,021.3 | |
| Debt / Equity | 1.07x | 1.02x | 0.71x |
*One export consignment caught fire at a warehouse near JNPT, costing INR 2.78 Cr. The company has filed an insurance claim; EBITDA margins were impacted by 42 bps and are expected to be corrected post receipt of the insurance claim.
Operating revenue and EBITDA increased each year from FY24 to FY26. The report attributes the FY26 performance to healthy demand, improved realisations, operating efficiencies and a growing contribution from specialty and value-added products.
Valuation and Target Price
The valuation is based on FY28 PAT and a target P/E of 36.0x. The report models 22.5% CAGR growth till FY28, while noting that raw-material volatility, capex and possible cost overruns may pressure margins. It gives a target price of INR 4,288 against a current market price of INR 3,386, with potential upside of 26.6%; the report’s rating rationale categorises upside above 15% as Buy.
- INR 3,386.3/-
- CMP
- INR 4,288
- Target price
- 26.6%
- Potential upside
- Buy
- Rating
Key Risks
- Raw-material and logistics costs: The report notes that Q1 FY27 EBITDA grew slower than revenue as FY26’s low-cost raw-material window faded. Chemical input and logistics cost fluctuations may affect margins in the short term.
- Capex execution and new products: Phase I slipped by a quarter. The report estimates the upper end of total phase capex at ~INR 1,400 Cr and notes that offtake contracts for new chemistries are yet to be signed; management expects FY28 to be a transition year.
- Working-capital intensity: Inventory days remain around 120 days, reflecting transit times of 60–130 days and buffer-stock needs. The report cautions that normalisation of trade payables could increase NWC.
- Lower promoter holding: Promoter holding fell from 69.9% in Sep’25 to 60.6% in Sep’26, including a block sale in Dec’25.
Competitive Advantages
- CST backward integration: The company processes crude sulphate turpentine, a paper-mill by-product, into captive alpha/beta pinene at a 36,000 MTPA facility. The report estimates a ~15–20% cost edge over the gum-turpentine route and notes contracted CST supply from 60–70+ pulp mills in Europe and North America.
- Givaudan joint venture: The 51:49 Privi–Givaudan JV makes 40+ specialty molecules exclusively for Givaudan. It turned PAT-positive in Q4 FY26; the partners infused INR 50 Cr of equity and Givaudan is extending a ~INR 180 Cr interest-free trade advance to reduce JV debt.
- Research and development: Two R&D centres in Mahad and Nerul have a team of 117. R&D spending is ~3% of operating income, supporting product development and entry into premium segments such as fine fragrances and bio-based chemicals.
Aroma Chemicals Industry
The report values the global aroma chemicals sub-market at US$ 6.1 billion in CY 2025 and projects US$ 9.9 billion by CY 2034, at a CAGR of 5.7%. Synthetic aroma chemicals dominate volumes, while demand for natural and bio-based ingredients is expanding.
- China + 1 sourcing: Geopolitical tensions, environmental enforcement and high energy costs are prompting fragrance and FMCG companies to diversify supply chains toward Indian partners.
- Natural and clean-label ingredients: Demand is increasing for plant-based, eco-friendly, bio-derived and biodegradable ingredients, encouraging investment in biotechnology and renewable feedstocks.
- Premium fragrance demand: Lifestyle changes in emerging markets are supporting demand for fine fragrances, functional wellness scents and gender-neutral fragrances.
- Industry challenges: The report identifies high entry barriers, regulatory stringency and raw-material volatility as structural challenges.
Peer Comparison
The report identifies S H Kelkar as a comparable peer. It says Privi recorded higher revenue growth and EBITDA margins, attributing the difference to backward integration, operating efficiencies and a shift toward higher-value specialties.
| Particulars | Privi Speciality Chemicals | S H Kelkar & Co. |
|---|---|---|
| Operating Revenue | 2,564 | 2,368 |
| Growth Y-o-Y % | 22.0% | 12% |
| EBITDA | 646.2 | 242 |
| EBITDA % | 25.2% | 10.2% |
| PAT | 316.7 | 69 |
| PAT % | 12.3% | 2.9% |
| Debt / Equity | 0.71x | 0.76x |
Management
The report states that Mr. Mahesh Babani and Mr. D.B. Rao manage the company’s operations and that the board comprises experienced professionals.
Our View
The report’s thesis rests on capacity additions, new products, customer relationships and CST integration supporting growth and margins. It sets a target price of INR 4,288, implying 26.6% potential upside and a Buy classification under its rating rationale. Capex delivery, new-product offtake and input-cost volatility are material risks to that outlook.
Standard disclosures
- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past 12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
- Nature of financial interest in subject company, if any –Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report - No.
- We or our Associates or Research Analyst are engaged in market making of subject company – No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.
Regulatory disclosures
Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com | Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In
- Equity Research Analysts: (a) Mr. Shubham Upadhyay (shubham.upadhyay@mcapital.in) (b) Mr. Nishant Gupta (nishant.gupta@mcapital.in)
Rating rationale
Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.
- Buy: > 15%
- Hold: - 5% to 15%
- Reduce: - 15% to - 5%
- Sell: < - 15%